Accession Number:

ADA434863

Title:

Interferon Alfacon1 is a Potent Inhibitor of SARS-Corona Virus in Cell-Based Models

Descriptive Note:

Corporate Author:

ARMY MEDICAL RESEARCH INST OF INFECTIOUS DISEASES FORT DETRICK MD

Report Date:

2005-01-04

Pagination or Media Count:

5.0

Abstract:

Preliminary data examining interferon alphacon1 treatment of SARS-CoV severe acute respiratory syndrome-corona virus-infected patients suggest this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection CPE assay, interferon alfacon1 inhibited the generation of CPE in a dose-dependent manner with an IC50 of 0.001 gml, a clinically achievable level. Furthermore, interferon alphacon1 also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alphacon1 against SARS-CoV suggests continued evaluation of interferon alphacon1 as a therapeutic treatment for patients infected with SARS-CoV.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research
  • Microbiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE